

# Treatment of locally advanced or metastatic transitional cell carcinoma with cabazitaxel

<b>Submission date</b> 01/11/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 26/02/2013	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/03/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerresearchuk.org/cancer-help/trials/a-trial-cabazitaxel-for-transitional-cell-bladder-cancer-that-has-spread-cab-b1>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Anjali Zarkar

### Contact details

Queen Elizabeth Hospital Birmingham  
Cancer Centre  
Edgbaston  
United Kingdom  
B15 2TH

-  
anjali.zarkar@uhb.nhs.uk

## Additional identifiers

### ClinicalTrials.gov (NCT)

NCT01668459

### Protocol serial number

RRK4368

## Study information

**Scientific Title**

Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy

**Acronym**

Cab B1

**Study objectives**

The study aims to compare the overall response rate of cabazitaxel treatment versus best supportive care including single agent chemotherapy in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

NRES Ethics Committee East Midlands - Leicester, 15/10/2012, ref: 12/EM/0363

**Study design**

Randomised open-label parallel-group study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Transitional cell carcinoma

**Interventions**

Cabazitaxel versus Best Supportive Care

Treatment duration: Up to 6 three weekly cycles of chemotherapy (18 weeks)

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Cabazitaxel

**Primary outcome(s)**

Overall response rate. Time Frame: Change from baseline at Week 9 and Week 18

**Key secondary outcome(s)**

1. Overall survival: Defined as the time interval from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time will be censored at the earlier of the last date the patient is known to be alive and the study cut-off date. Time Frame: From date of randomisation to the date of tumour progression or death (from any cause) (or survival at study cut-off date), whichever came first up to 12 months after the final patient has completed study treatment.
2. Quality of life, assessed using a validated instrument; the EuroQOL (EQ-5D). Time Frame: Change from baseline at Week 6, Week 12, Week 18, Week 21
3. Safety and tolerability: Dose delays and dose reductions, adverse events, laboratory safety data. Time Frame: From date of randomisation up to 30 days after final dose of study medication

**Completion date**

31/12/2015

## Eligibility

**Key inclusion criteria**

1. Written informed consent
2. Age  $\geq$  18
3. Life expectancy  $\geq$  12 weeks
4. Patients with histology/cytology confirmed Transitional Cell Carcinoma (TCC) including mixed pathology with predominantly TCC, with locally advanced (T4b) or metastatic (lymph node or visceral) TCC arising from bladder or upper urinary tracts
5. Treated patients with incidental prostate cancer (pT2, Gleason  $\leq$  6) and PSA (Prostate Specific Antigen)  $\leq$  0.5 ng/mL are eligible
6. Measurable disease as per RECIST Criteria 1.1
7. ECOG Performance Status 0-1
8. Previously received first line platinum based treatment
9. Recurrence within 12 months (by RECIST criteria version 1.1) from last cycle of chemotherapy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Previous therapy with a taxane
2. Pure non TCC histologies
3. Grade II or more peripheral neuropathy

4. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrolment in the study
5. Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
6. Inadequate organ and bone marrow function as evidenced by:
  - 6.1. Hemoglobin < 9.0 g/dL
  - 6.2. Absolute neutrophil count <  $1.5 \times 10^9/L$
  - 6.3. Platelet count <  $100 \times 10^9/L$
  - 6.4. AST/SGOT and/or ALT/SGPT >  $2.5 \times ULN$
  - 6.5. Total bilirubin >  $1.0 \times ULN$
  - 6.6. Serum creatinine >  $1.5 \times ULN$ . If creatinine  $1.0 - 1.5 \times ULN$ , creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance  $\leq 30$  mL/min should be excluded
7. Symptomatic brain metastases or leptomeningeal disease (CT or MRI scan of the brain required only in case of clinical suspicion of central nervous system involvement)
8. History of another neoplasm except non-metastatic melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery, small field radiation or chemotherapy < 5 years prior to randomization
9. History of inflammatory bowel disease, significant bowel obstruction
10. History of hypersensitivity to platinum, gemcitabine, taxanes, Polysorbate-80, or to compounds with similar chemical structures
11. Any of the following events within 6 months prior to randomization: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft surgery, clinically symptomatic and uncontrolled cardiovascular disease, or clinically significant arrhythmias (grade 3-4)
12. Concurrent treatment with strong inhibitors of cytochrome P450 3A4 or patients planning to receive these treatments. For patients who were receiving treatment with such agents, a one-week washout period is required prior to randomization
13. Women who are breastfeeding and women of child bearing potential (not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus)) unless in agreement to use an adequate method of contraception during the treatment period and for 6 months after the last dose of the study drug. Men unless in agreement that they will use effective contraception (and condom to protect against exposure to seminal liquid) whilst participating in the trial and for 6 months after the last dose of study medication

**Date of first enrolment**

01/12/2012

**Date of final enrolment**

31/12/2015

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

Queen Elizabeth Hospital Birmingham  
Edgbaston

United Kingdom  
B15 2TH

## Sponsor information

### Organisation

University Hospitals Birmingham NHS Foundation Trust (UK)

### ROR

<https://ror.org/014ja3n03>

## Funder(s)

### Funder type

Industry

### Funder Name

Sanofi Aventis (France)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	20/05/2017		Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No